by the isolated perfused rabbit heart has chromatographic mobility similar to that of PGE2 in most solvent systems. However, additional analysis of this radioactive "PGE" peak suggests that two substances are formed by the heart and migrate like PGE2: one has chemical properties similar to those of authentic PGE2 and the other is a novel PG. The unknown compound is the major PG formed by the heart from either exogenous arachidonate or hormonal stimulation of PG biosynthesis. The novel PG produced by the heart may be identical with either 6(9)oxy-PGF or 6-keto-PGFia.
Synthesis and release of prostaglandins (PGs) by intact tissues occurs in response to various stimuli, both noxious and hormonal. The sequence of events leading to the release of PGs is thought (1, 2) to be initiated by the activation of phospholipase A2 (phosphatide 2-acyl-hydrolase, EC 3.1.1.4) which liberates arachidonate (the major substrate for the cyclo-oxygenase) from the 2-position of phospholipids. The free arachidonate is then available for conversion to PGs (3) . Various stimuli including decreased oxygen tension (4, 5) , mechanical damage (6), hormones such as bradykinin (7) and angiotensin 11 (8) , and arachidonate itself (9) release PGs from the isolated perfused rabbit heart. The PGs released have generally been characterized as PGE-like by bioassay. We recently described a method for studying the products of arachidonate metabolism (both exogenous and endogenous) in intact tissues by prelabeling the cardiac phospholipids with [14C]arachidonate (10) . In the present work, in which we applied this method to the study of arachidonate metabolism in the intact rabbit heart, we found that the major PG formed by the heart is not PGE2 but is, in fact, a novel PG.
METHODS
The hearts were removed from male New Zealand rabbits anesthetized with pentobarbital and perfused at 30 ml/min with Krebs-Henseleit buffer (370; atmosphere, 95% 02/5% CO2) as previously described (5) .
The method for incorporating radioactive arachidonate into heart lipids has been described in detail elsewhere (10) . Briefly, 5 ACi of [14C]arachidonic acid (Amersham/Searle; specific activity 55 mCi/mmol) prepared as the Na salt in saline (pH 9.0) was infused through the coronary vascular bed for 20 min.
The ['4C]arachidonate is efficiently incorporated into endogenous tissue lipids and later can be released in the form of 4C-labeled PGs by agents which stimulate PG biosynthesis.
The coronary vasculature effluent was monitored for radioactive PGs by collection of 50-to 100-mI samples, convenAbbreviations: PG, prostaglandin; 6(9)-oxy-PGF, 6(9)-oxy-11,15-dihydroxyprosta-7,13.dienoic acid.
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tional acid-lipid extraction, and thin-layer chromatography as previously described (10) . Solvent (14) , with 2.4 mM norepinephrine included in each incubation. RESULTS Products from Exogenous Arachidonic Acid. Infusion of arachidonic acid through the coronary vasculature of the isolated rabbit heart produces coronary vasodilation and concomitant appearance of a PG-like substance in the effluent (9) . On analysis of the effluent from the coronary vasculature by thin-layer chromatography in system C, a characteristic pattern of products was obtained (Fig. 1B) . A prominent peak of radioactivity was seen associated with PGE2, and a lesser amount was associated with PGF2,,. Chromatography of another portion of the same coronary vasculature effluent sample in system BDA produced a radically different pattern; in this system, authentic 14C-labeled PGE2 ran as a single peak (Fig. IA, lower panel). In this solvent system, the major peak of radioactivity had a chromatographic mobility similar to that of PGF2,a Chromatography in solvent system E and on AgNO3-impregnated plates (system SN) produced patterns similar to those seen in system C (i.e., the major radioactive peak had mobility similar to that of PGE2) (data not shown).
Chemical Characterization of "PGE" Peak. Several samples obtained during infusion of [14C]arachidonate were pooled, concentrated, and chromatographed in system C. The radioactive peak migrating with PGE2 was scraped off and eluted twice with methanol to obtain material for further chemical characterization. Treatment of this "PGE" peak material with 2 M KOH in methanol at 65°for 60 min (15) resulted in only partial conversion to PGB2 (Fig. IC, upper panel) . In contrast, standard "lC-abeled PGE2 treated similarly was quantitatively converted to PGB2 (Fig. iC, lower panel) . Furthermore (Fig. 2C) . Thus, a PG comparable to the novel PG is-not formed from the C203 acid' (which lacks the 5-6 double bond).
Products Formed from Endogenous Arachidonic Acid. Hearts prelabeled with ['4C]arachidonate will release radioactive PGs when synthesis is stimulated by such agents as bradykimnn and ATP (10) . The predominant peak of radioactivity after such stimulation migrated-with PGE2 in system C ( Fig. 3A and C) , without demonstrable PGF2a present. However, when similarly obtained samples were chromatographed in system BDA, two peaks were observed ( Fig. 3B and D (14, 16) have conclusively demonstrated, with gas chromatography-mass spectrometric methods, that the primary arachidonate products produced by homogenates of rat gastric fundus are 6(9)oxy-PGF and 6-keto-PGFIa. We used the rat stomach preparation to generate this material for comparison to the cardiac compound. After incubation of [14C]arachidonate with homogenates of rat fundus, extraction and chromatography in system C gave one major peak with chromatographic mobility similar to that of PGE2 (Fig. 5A) , confirming the results of Pace-Asciak and Wolfe (16) . However, rechromatography of this "PGE" peak in system BDA produced a change in mobility such that the major peak of radioactivity moved with PGF2a (Fig. 5B) . This change was identical to that observed with the "PGE" peak isolated by system C from the coronary vasculature effluent (Fig. 5B, lower panel) . Apparently, this novel PG is somewhat unstable: isolation of the radioactive "PGE" peak in system BDA followed by rechromatography in system C apparently decomposes the compound (Fig. 5C ). When the system BDA "PGF" peak from rat fundus was so treated, a similar pattern of decomposition products was obtained (Fig. 5C ). This provides an additional useful method for comparing the cardiac compound with the PGs formed by rat fundus. A. Chromatography of incubation products in system C. B. Radioactive peak migrating with PGE2 in system C was eluted and chromatographed in system BDA. C. Radioactive peak migrating with PGF2a in system BDA was eluted and chromatographed in system C. Lower panels. The radioactive peak from [14C]arachidonate infusion in rabbit heart and migrating with PGE2 in system C was isolated as before. A. Rechromatography in system C. B. Chromatography in system BDA. C. Radioactive peak migrating with PGF2a in system BDA was eluted and chromatographed in-system C.
DISCUSSION
The release of PG-like material from the isolated perfused rabbit heart has been studied in several laboratories. The identity of this material has generally been described as PGElike on the basis of chromatographic mobility and bioassay characteristics. Thus, it was surprising to find that the major PG product obtained from exogenous [14C]arachidonate and by hormone-stimulation of endogenous arachidonate release had chemical and chromatographic properties distinct from those of PGE2. The assignment of a non-PGE2 structure to the major PG produced by the heart is based on its chromatographic mobility, resistance to alkali conversion to PGB2, and resistance to acid conversion to PGA2. Although the data do not allow complete structural identification of the compound, they do suggest the lack of a #-OH-ketone structure (as in PGE2 and PGD2, which are sensitive to alkali treatment). Recently, Pace-Asciak and Wolfe (14, 16) have reported the structures (determined by gas chromatography-mass spectrometry) of two novel PGs formed by rat fundus homogenates: (f) 6(9)oxy-PGF, and (ii) 6-keto-PGFI.. Both of these PGs have certain properties in common with the unknown compound reported here i.e., chromatographic mobility similar to that of PGE2 in most solvent systems and resistance to alkali conversion to PGB2. The experiments with rat fundus homogenates reported here demonstrate two other striking similarities: (i) both the unknown compound formed by the heart and the products obtained from rat fundus homogenates have chromatographic mobility identical with that of PGF2a in system BDA, and (Ui) the system BDA "F" peaks from both give coincident decomposition products.
The proposed mechanisms for the formation of both compounds by rat fundus involve oxygen attack at the C-6 position of the 5, 6 double bond of arachidonate. Thus, a PG-precursor fatty acid which lacks the 5,6 double bond (e.g., 8 ,11,14-eicosatrienoic acid) would not be converted to either 6(9)oxy-PGF or 6-keto-PGFia. We could find no evidence of the conversion of the C20:3 acid in heart to the unknown compound formed from arachidonate, although PGE1 and PGFia were produced from this acid. These results therefore suggest that the novel PG formed by rabbit heart may be identical with 6(9)oxy-PGF or 6-keto-PGF1a. Confirmation of this WilI require structural identification of this compound by mass spectrometry. Proposed structures of the compounds produced by rabbit heart are shown in Fig. 6 .
It has been suggested that the coronary dilation produced by arachidonic acid or bradykinin in the rabbit heart is due to PGE2 (1, 8 The implications of this work can be extended to other tissues. For example, the PGs produced by many organs have been identified as PGE2 on the basis of chromatographic mobility in one solvent system. These results should be reevaluated in light of the present report. Furthermore, the biological activity of material believed to be PGE2 should be compared to that of these novel PGs. The production of novel PGs in good yield from tissues as disparate as rat gastric fundus and rabbit heart justifies further search for these compounds in other tissues and extensive examination of their biological activity.
Note Added in Proof. We have recently found that isolated bovine coronary arteries convert arachidonic acid to a compound similar to that reported here (18) . Moncada et al. (19) have shown that rabbit aorta microsomes convert PGH2 to an unstable compound that inhibits platelet aggregation and relaxes vascular smooth muscle. We have found that microsomes from bovine coronary artery produce a similar compound from PGH2 that is a potent coronary artery relaxant. Furthermore, in recent experiments we have found that the isolated rabbit heart, upon stimulation of PG biosynthesis (by arachidonate or bradykinin), releases a substance which relaxes bovine and canine coronary arteries and its synthesis is inhibited by indomethacin. These results suggest that an intermediate in the synthesis of the novel PG reported here is a potent coronary vasodilator and may be important in the regulation of coronary vascular resistance. 
